How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Advanced Therapy Based on Gene Market
- By Therapy Type: Gene Therapy, Cell Therapy, Tissue Engineering, Gene Editing (CRISPR/Cas9), RNA Therapy
- By Vector Type: Viral Vectors (Adeno-associated virus, Lentivirus), Non-viral Vectors (Lipid nanoparticles, Electroporation)
- By Indication: Oncology, Rare Genetic Disorders, Cardiovascular Diseases, Neurological Disorders, Autoimmune Diseases
- By End User: Hospitals and Clinics, Research Institutes, Contract Manufacturing Organizations (CMOs), Academic and Government Research Laboratories
- By Delivery Method: In vivo Delivery, Ex vivo Delivery
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Gene Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Advanced Therapy Based on Gene Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Vector Type 2
Indication 5
End User 4
Delivery Method 2
Companies profiled
Novartis AG
Gilead Sciences
Inc. (Kite Pharma)
Bristol-Myers Squibb (Celgene)
Bluebird Bio Inc.
Sangamo Therapeutics Inc.
UniQure N.V.
Spark Therapeutics
Inc. (a Roche company)
REGENXBIO Inc.
AveXis
Inc. (a Novartis company)
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb (Celgene)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sangamo Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →UniQure N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Spark Therapeutics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Inc. (a Roche company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →REGENXBIO Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AveXis
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Inc. (a Novartis company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Homology Medicines Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Audentes Therapeutics (a part of Astellas Pharma)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →MeiraGTx Holdings plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Cellectis S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Poseida Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Adaptimmune Therapeutics plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,651M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Gene Therapy42.6
- Cell Therapy9.6
- Tissue Engineering14.9
- Gene Editing (CRISPR/Cas9)11.0
- RNA Therapy22.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,308M → $1,949M · 5.1%
Europe$911.9M → $1,617M · 7.4%
Asia Pacific$832.6M → $1,430M · 7.0%
Latin America$515.4M → $895.0M · 7.1%
Middle East and Africa$396.5M → $647.4M · 6.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.642026
6.642027
6.652028
6.672029
6.682030
6.682031
6.702032
6.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG18.4
- Gilead Sciences25.1
- Inc. (Kite Pharma)8.9
- Bristol-Myers Squibb (Celgene)8.0
- Bluebird Bio Inc.5.5
- Sangamo Therapeutics Inc.6.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type25.0%
Vector Type19.4%
Indication14.2%
End User20.4%
Delivery Method20.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.8
- Europe24.7
- Asia Pacific21.9
- Latin America13.7
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 76 | 89 | 90 | 78 | 95 | 84 | 85 |
| Gilead Sciences | 85 | 89 | 82 | 90 | 73 | 80 | 83 |
| Inc. (Kite Pharma) | 74 | 79 | 65 | 73 | 66 | 79 | 73 |
| Bristol-Myers Squibb (Celgene) | 61 | 67 | 81 | 63 | 73 | 60 | 68 |
| Bluebird Bio Inc. | 67 | 70 | 73 | 68 | 74 | 60 | 69 |
| Sangamo Therapeutics Inc. | 59 | 71 | 61 | 64 | 69 | 54 | 63 |
| UniQure N.V. | 61 | 66 | 65 | 62 | 64 | 45 | 61 |
| Spark Therapeutics | 50 | 56 | 46 | 59 | 45 | 51 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Gilead Sciences | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Inc. (Kite Pharma) | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Bristol-Myers Squibb (Celgene) | − | ◐ | ✓ | ◐ | ✓ | ◐ |
| Bluebird Bio Inc. | ◐ | ◐ | ✓ | ◐ | ◐ | − |
| Sangamo Therapeutics Inc. | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| UniQure N.V. | − | ◐ | − | ◐ | ◐ | − |
| Spark Therapeutics | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG85
2Gilead Sciences83
3Inc. (Kite Pharma)73
4Bluebird Bio Inc.69
5Bristol-Myers Squibb (Celgene)68
6Sangamo Therapeutics Inc.63
7UniQure N.V.61
8Spark Therapeutics51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Novartis AGGilead Sciences
Challenger3
Strong scale, closing on the leaders.
Inc. (Kite Pharma)Bristol-Myers Squibb (Celgene)Bluebird Bio Inc.
Contender2
Focused players with pockets of strength.
Sangamo Therapeutics Inc.UniQure N.V.
Niche1
Specialists in a single segment or region.
Spark Therapeutics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Advanced Therapy Based on Gene Market — a $160M beachhead inside a $2.52B market.
Beachhead (SOM)$160Mobtainable near-term
Serviceable (SAM)$876Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Gene Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer76 fit
Cell Therapy
Strong fit — clear ROI and a fast path to value.
End user68 fit
Tissue Engineering
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vector Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Advanced Therapy Based on Gene Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified23%
Evaluation12%
Closed-won5%
$15.1KCAC
$64KLTV
4.2:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Advanced Therapy Based on Gene Market is a high-growth opportunity — $3.61B by 2033, compounding at 10.3%.
TAM · 2025$1.64Btoday
TAM · 2033$3.61Bforecast
CAGR10.3%2027–2033
Cumulative$22.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.61BTotal addressable market
SAM$1.43BServiceable available market
SOM$255MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.3% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.61BLarge & growingTAM by 2033 at 10.3% CAGR
$1.43BServiceable nowreachable with today’s model
$255MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.82BBear6.7% CAGR
$3.61BBase10.3% CAGR
$4.62BBull13.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vector Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Advanced Therapy Based on Gene Market — a $9.06B market by 2033. Plan: grow share from 8.4% to 17.6%.
Market size · 2033$9.06Btotal addressable
Market CAGR11.4%2027–2033
Target share17.6%from 8.4% today
Revenue ambition$1.59Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 17.6% | On track |
| Revenue | $706M | $1.59B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 31.2% | 44.7% | On track |
| Customer retention | 85.5% | 94.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vector Type capability
A defensible second engine — invest in Vector Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vector Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $225M capacity & capability investment
- Greenlight bolt-on M&A in Vector Type
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Advanced Therapy Based on Gene Market conversation — a $6.87B market you can size, segment and defend in minutes.
Market size · 2033$6.87Btotal opportunity
Growth11.1%CAGR to 2033
Addressable buyers1,665+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 2 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Novartis AGGilead SciencesInc. (Kite Pharma)Bristol-Myers Squibb (Celgene)Bluebird Bio Inc.Sangamo Therapeutics Inc.UniQure N.V.Spark Therapeutics+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Advanced Therapy Based on Gene Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Advanced Therapy Based on Gene Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Heart Disease Insurance Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportElectronic Data Capture Software Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportAdvanced Surgical Imaging System Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAdvanced Sterilization Product Market
Market size, share, segmentation and regional forecast.
$827M market · 2025 base year
View reportBiopharmaceutical Cold Chain Transport Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportBiopharmaceutical Transport Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportAdvanced Sports Medicine Product Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAdvanced Silver Wound Dressing Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportChild Nutrition Monitoring and Data Analysis Software Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportAdvanced Securement Dressing Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportAdvanced Scar Gel Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAdvanced Scar Dressing Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.